According to KDIGO guidelines, should an SGLT2 inhibitor be started in a patient with type 2 diabetes and eGFR ≥ 20 mL/min/1.73 m² only if albuminuria (urine albumin‑to‑creatinine ratio ≥ 30 mg/g) is present?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 27, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

No, KDIGO Does Not Require Albuminuria for SGLT2 Inhibitor Initiation in Type 2 Diabetes with eGFR ≥20

The 2024 KDIGO guidelines provide an unconditional 1A recommendation to treat ALL patients with type 2 diabetes, CKD, and eGFR ≥20 mL/min/1.73 m² with an SGLT2 inhibitor, regardless of albuminuria status 1.

The Guideline Structure is Clear

The KDIGO 2024 guideline establishes a tiered approach:

  • Recommendation 3.7.1 (1A): Start SGLT2i in ALL patients with T2D, CKD, and eGFR ≥20 mL/min/1.73 m² - no albuminuria requirement 1

  • Recommendation 3.7.2 (1A): For adults with CKD (with or without diabetes), SGLT2i is recommended when eGFR ≥20 AND either:

    • Urine ACR ≥200 mg/g, OR
    • Heart failure (regardless of albuminuria) 1

  • Recommendation 3.7.3 (2B): For adults with eGFR 20-45 AND ACR <200 mg/g, SGLT2i is suggested (weaker recommendation) 1

Why This Matters Clinically

The distinction is critical: if you have a patient with type 2 diabetes and eGFR ≥20, you should start an SGLT2 inhibitor even with completely normal albumin excretion (ACR <30 mg/g). The albuminuria thresholds only apply to the broader CKD population without diabetes or those with lower eGFR ranges.

Recent meta-analysis data strongly support this approach, demonstrating that SGLT2 inhibitors reduce CKD progression across all albuminuria categories, including those with ACR ≤30 mg/g (HR 0.58,95% CI 0.44-0.76) 2. The benefit persists even in nonalbuminuric kidney disease, with significant reductions in progression to macroalbuminuria and all-cause mortality 3.

Common Pitfall to Avoid

Do not withhold SGLT2 inhibitors from patients with type 2 diabetes and preserved kidney function simply because they lack albuminuria. The evidence shows benefit across the entire spectrum of kidney function and albuminuria, and the strongest guideline recommendation (1A) applies to all T2D patients with eGFR ≥20, making albuminuria testing unnecessary for treatment initiation in this population.

Once initiated, continue the SGLT2i even if eGFR falls below 20 mL/min/1.73 m² unless dialysis is started or the medication is not tolerated 1, 4.

References

Related Questions

In a patient with type 2 diabetes and eGFR ≥30 mL/min/1.73 m², when is it appropriate to initiate an SGLT2 inhibitor and what starting dose should be used?
When is it appropriate to initiate an SGLT‑2 inhibitor and what are the recommended dosing and contraindications?
In an adult with type 2 diabetes and an estimated glomerular filtration rate of at least 20 mL/min/1.73 m², which sodium‑glucose cotransporter‑2 (SGLT2) inhibitor can be initiated regardless of albuminuria status?
According to KDIGO guidelines, should a sodium‑glucose co‑transporter‑2 (SGLT2) inhibitor be started in any adult with type 2 diabetes whose estimated glomerular filtration rate (eGFR) is ≥20 mL/min/1.73 m², regardless of albuminuria?
When should a SGLT‑2 inhibitor be started, dose‑adjusted, or discontinued based on a patient's estimated glomerular filtration rate (eGFR)?
What are the components of routine pediatric care (puericultura) at a basic health unit (UBS)?
What is the appropriate management for a 36‑week pregnant patient presenting with headache, seizure, and hypermagnesemia?
What is the appropriate prophylactic dosing and administration of ferrous sulfate for infants at a primary health care unit?
What is a normal left‑ventricular ejection fraction (EF) for a 40‑year‑old compared with a 50‑, 60‑, and 70‑year‑old?
How long should 5% minoxidil be left on the scalp before rinsing?
When should the serum magnesium level be rechecked after administering calcium gluconate in a patient on the obstetric unit?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.